Soloxine
Soloxine Price range: $ 34,00 through $ 83,00
Back to products
Sotret
Sotret Price range: $ 24,00 through $ 70,00

Sorbitrate

Price range: $ 18,00 through $ 38,00

Sorbitrate is a highly effective medication belonging to the nitrate class, specifically designed to support cardiovascular health. The active ingredient works by relaxing and widening the blood vessels, which significantly improves blood flow to the heart muscle. This medication is primarily used for the prevention and long-term management of angina pectoris caused by coronary artery disease. By reducing the overall workload on the heart, it helps to minimize the frequency and severity of chest pain episodes. Sorbitrate provides reliable support for individuals looking to maintain their daily activities while managing chronic heart conditions.

Active substance: isosorbide dinitrate
SKU: Sorbitrate Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Sorbitrate belongs to a class of cardiovascular medications known as organic nitrate vasodilators, which feature isosorbide dinitrate as the active pharmaceutical ingredient. It is an FDA-approved prescription medication indicated for the prevention and clinical management of angina pectoris resulting from underlying coronary artery disease.

As a prescription-only therapy in the United States, Sorbitrate must be administered under the direct supervision of a licensed healthcare provider. Dispensed in full compliance with applicable federal and state regulations, this agent reduces myocardial oxygen demand by relaxing vascular smooth muscle and improving hemodynamic parameters in patients with ischemic heart disease.

Property Details
Drug Name Sorbitrate
Active Ingredient Isosorbide dinitrate
Therapeutic Class Nitrate Vasodilator
Dosage Form Oral tablet, Sublingual tablet
Route of Administration Oral, Sublingual
Prescription Status Prescription only (Rx)

Clinical Overview and Pharmacological Profile

Main Uses and Mechanism of Action

How the drug works: Isosorbide dinitrate, the active component of Sorbitrate, exerts its therapeutic effect by relaxing vascular smooth muscle throughout the peripheral and coronary arterial beds. Upon systemic absorption, the molecule undergoes enzymatic biotransformation to release free nitric oxide (NO). Nitric oxide stimulates the enzyme soluble guanylate cyclase, increasing intracellular levels of cyclic guanosine monophosphate (cGMP). Elevated cGMP decreases intracellular calcium concentration, resulting in vasodilation. Venous dilation predominates over arterial dilation, leading to peripheral pooling of blood and reduced venous return to the heart. This decrease in left ventricular end-diastolic pressure and volume (preload) significantly reduces myocardial wall tension and oxygen consumption. Concurrently, mild arterial relaxation decreases systemic vascular resistance (afterload), further lowering the workload of the heart and relieving ischemic myocardial strain.

Main uses: Sorbitrate is explicitly indicated for the prophylaxis and long-term treatment of angina pectoris caused by coronary artery disease. Sublingual formulations are utilized for rapid relief of acute anginal attacks due to their swift onset of action, whereas oral immediate-release tablets are prescribed for chronic prophylaxis to decrease the frequency and severity of chest pain episodes. Any off-label applications–such as adjunctive therapy in managing chronic congestive heart failure when combined with hydralazine–must be evaluated and monitored by a qualified prescriber, as standard monotherapy with nitrates is not an FDA-approved primary treatment for heart failure. Sorbitrate is not indicated for the immediate treatment of an evolving acute myocardial infarction outside of specialized inpatient monitoring settings.

Pharmacokinetics and Administration Guidelines

How it’s absorbed and eliminated: Following oral administration, isosorbide dinitrate is rapidly absorbed from the gastrointestinal tract. However, it undergoes extensive first-pass hepatic metabolism, yielding an absolute systemic bioavailability of approximately 10% to 20% for oral formulations. Sublingual administration bypasses initial liver clearance, producing therapeutic blood concentrations within 2 to 5 minutes. Isosorbide dinitrate is metabolized in the liver into two active metabolites: isosorbide 2-mononitrate and isosorbide 5-mononitrate. The 5-mononitrate metabolite possesses significant hemodynamic activity and demonstrates a longer elimination half-life than the parent compound. Parent isosorbide dinitrate has a plasma elimination half-life of approximately 1 hour, whereas its active metabolites display half-lives ranging from 2 to 5 hours. Excretion is primarily renal, predominantly in the form of inactive glucuronide metabolites.

Dosing schedule: Dosing schedules for Sorbitrate are established individually by the prescribing physician based on clinical response, formulation, and patient tolerance. For maintenance therapy using oral tablets, typical initial adult regimens range from 5 mg to 20 mg taken two to three times daily. To prevent the development of nitrate tolerance–a physiological state in which clinical responsiveness decreases during continuous nitrate exposure–prescribers implement an asymmetrical dosing schedule incorporating a daily nitrate-free interval of 10 to 14 hours (for instance, administering doses at 8:00 AM and 1:00 PM). Sublingual tablets for acute anginal episodes are typically administered at 2.5 mg to 5 mg placed under the tongue at the onset of pain; doses may be repeated every 5 to 10 minutes, up to a maximum of three doses in 15 minutes during an acute episode.

Safety, Interactions, and Patient Guidance

Adverse Effects and Drug Interactions

Adverse reactions: The primary adverse effects associated with Sorbitrate stem directly from its systemic vasodilatory properties. Dose-dependent vascular headache is the most common side effect, frequently occurring at the start of therapy; these headaches typically lessen in intensity over days to weeks of continuous treatment. Orthostatic hypotension–causing dizziness, lightheadedness, or syncope upon standing–is common due to venous blood pooling. Additional adverse reactions include cutaneous facial flushing, reflex tachycardia, weakness, transient nausea, and vomiting. Severe hypotension may occasionally trigger paradoxical bradycardia and intensified anginal chest pain. Hypersensitivity reactions, including cutaneous rash or exfoliative dermatitis, occur rarely.

What not to combine: The concomitant use of Sorbitrate with phosphodiesterase type 5 (PDE5) inhibitors–including sildenafil, tadalafil, or vardenafil–is strictly contraindicated. Co-administration can cause precipitous, life-threatening drops in blood pressure resulting in cardiovascular collapse. Likewise, concurrent use with soluble guanylate cyclase stimulators (such as riociguat) is contraindicated due to additive hypotensive risks. Caution is warranted when combining Sorbitrate with other blood-pressure-lowering medications, including beta-blockers, calcium channel blockers, ACE inhibitors, diuretics, or alcohol, as these substances can enhance vasodilatory effects and increase the risk of symptomatic hypotension and syncope.

Precautions and Emergency Considerations

Important precautions: Sorbitrate should be prescribed with heightened caution in patients with severe anemia, closed-angle glaucoma, severe cerebral hemorrhage, or recent head trauma, because vasodilatory changes may increase intracranial or intraocular pressure. Patients with volume depletion, low baseline blood pressure, or hypertrophic obstructive cardiomyopathy require careful evaluation before initiating therapy. In elderly populations, dosage selection should be conservative, starting at the low end of the dosing spectrum due to higher rates of decreased hepatic, renal, or cardiac function. Use during pregnancy should occur only if clearly indicated after a careful benefit-risk analysis by the provider. It remains unknown whether isosorbide dinitrate is excreted in human milk; caution must be exercised when administering the drug to nursing mothers.

Red flags: Emergency medical care must be sought immediately if a patient experiences signs of severe hypersensitivity or acute hemodynamic instability. Critical red flags include:

  • Swelling of the face, lips, tongue, or throat, or difficulty breathing
  • Severe, persistent chest pain that fails to subside after three sublingual doses within 15 minutes
  • Severe dizziness, fainting, or loss of consciousness
  • Unusually slow or rapid, irregular heartbeat
  • Bluish coloration of the skin, lips, or fingernails (cyanosis), which may indicate methemoglobinemia

If you skip a dose: If a scheduled oral dose of Sorbitrate is missed, it should be taken as soon as remembered, unless it is close to the time for the next scheduled dose. If the next dose is near, skip the missed dose and resume the regular dosing schedule. Never double the dose to compensate for a missed tablet, as taking extra medication significantly increases the risk of severe hypotension and incapacitating headaches.

What to avoid while taking it: Patients taking Sorbitrate must avoid consuming alcohol, as ethanol potentiates systemic arterial and venous dilation, dramatically increasing the risk of orthostatic hypotension and syncope. Patients should also avoid sudden posture changes, such as standing up rapidly from a lying or seated position, to minimize dizziness. Oral tablets may be taken with or without food, but maintaining a consistent pattern relative to meals helps ensure stable absorption.

Storage and expiration: Store Sorbitrate tablets at controlled room temperature between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). Keep the container tightly closed and protect the medication from excessive moisture and heat. Sublingual formulations should remain in their original glass container to preserve potency. Store out of the reach of children and properly dispose of any expired or unused medication in accordance with local guidance.

Common Questions

Why is a nitrate-free interval required when taking Sorbitrate daily?

Continuous 24-hour exposure to nitrates leads to vascular tolerance, a condition where the vascular smooth muscle becomes less responsive to the medication, diminishing its anginal prevention effects. Establishing an daily nitrate-free period (typically 10 to 14 hours, often overnight) restores vascular sensitivity and maintains the long-term effectiveness of the drug.

What should be done if a headache occurs after taking Sorbitrate?

Headaches are a known pharmacological effect caused by dilation of cranial blood vessels. They often decrease in severity after a few days or weeks of consistent therapy. Patients may discuss taking mild over-the-counter analgesics with their healthcare provider. Headaches should not be treated by skipping doses without clinical advice, as abrupt discontinuation can trigger rebound angina.

Can Sorbitrate be taken at the same time as erectile dysfunction drugs?

No. Sorbitrate must never be taken concurrently with PDE5 inhibitors such as sildenafil, tadalafil, or vardenafil. Combining these medications can trigger severe, unpredictable drops in blood pressure that may lead to heart attack, stroke, or death. Patients must inform their physician of all medications they take prior to receiving a nitrate prescription.

Is it safe to drive or operate machinery while taking Sorbitrate?

Sorbitrate can cause dizziness, lightheadedness, and fainting, particularly when initiating treatment or adjusting doses. Patients should refrain from driving, operating heavy machinery, or performing hazardous tasks until they understand how the medication personally affects their alertness and hemodynamic stability.

How rapidly do sublingual Sorbitrate tablets work during chest pain?

Sublingual tablets dissolve under the tongue and bypass first-pass liver metabolism, entering the bloodstream rapidly. Clinical effect generally begins within 2 to 5 minutes. If chest pain persists after taking one sublingual tablet, emergency medical services (such as dialing 911) should be alerted while taking additional doses according to doctor instructions.

This text is for informational purposes only and does not constitute individual medical advice. In accordance with FDA requirements.

Additional information
Dosage

5 mg

,

10 mg

Package

50 tabs

,

100 tabs

,

150 tabs

,

200 tabs

Ενεργός Ουσία